GlassScriptPhysician profile
Priya Jayachandran
NPI 1962768671
$279.01
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $82.13 · 2020: $154 · 2021: $13.84 · 2023: $28.98.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $28.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $28.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $48.85 | 2019 | |
| Blueprint Medicines Corporation | $30.08 | 2020 | |
| Puma Biotechnology, INC. | $28.98 | 2023 | |
| Celgene Corporation | $22.99 | 2020 | |
| Incyte Corporation | $21.99 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $20.84 | 2020 | |
| Alexion Pharmaceuticals, INC. | $20.41 | 2020 | |
| Merck Sharp & Dohme LLC | $19.68 | 2020 | |
| Jazz Pharmaceuticals INC. | $18.07 | 2020 | |
| Eisai INC. | $17.20 | 2019 | |
| Novartis Pharmaceuticals Corporation | $16.08 | 2019 | |
| Lilly USA, LLC | $13.84 | 2021 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Priya Jayachandran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.